Core Viewpoint - The company Kintor Pharmaceutical (科济药业-B) has announced a clinical collaboration with Dispatch Bio to initiate a Phase I clinical trial in China by 2026, focusing on a combination therapy for solid tumors [1][5]. Group 1: Company Developments - Kintor Pharmaceutical's stock price increased by 4.22%, currently trading at HKD 16.31, with a trading volume of HKD 7.3022 million [1][5]. - The collaboration with Dispatch Bio involves the evaluation of the combination therapy DISP-11, which includes Dispatch's novel tumor-specific virus DV-10 and Kintor's targeted BCMA autologous CAR-T cell product, Kintor's ZKAB (泽沃基奥仑赛注射液) [1][5]. - Kintor's ZKAB has already received approval from the National Medical Products Administration (NMPA) in China for the treatment of multiple myeloma [1][5].
科济药业-B午前涨超4% 近日宣布与Dispatch Bio达成合作